Clinical Trials
18 trialsNCT06843447 2026-05-26
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT04657068 2026-03-18
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1/2 Recruiting
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT03314935 2025-08-12
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT04068896 2025-05-29
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
NGM Biopharmaceuticals, Inc
Phase 1/2 Completed
NCT02632448 2025-05-02
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Esperas Pharma Inc.
Phase 1/2 Completed
NCT03997968 2024-12-24
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Cyteir Therapeutics, Inc.
Phase 1/2 Completed
NCT06055348 2023-09-26
SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer
Biocity Biopharmaceutics Co., Ltd.
Phase 1/2 Unknown
NCT01133756 2023-06-22
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Eisai Inc.
Phase 1/2 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT00390182 2020-03-18
GCC0319
University of Maryland, Baltimore
Phase 1/2 Completed
NCT01663857 2019-09-11
A Study LY2228820 for Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT00910000 2018-09-10
Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00184093 2017-08-15
Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma
University of Southern California
Phase 1/2 Completed
NCT01624493 2015-12-23
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
Hoosier Cancer Research Network
Phase 1/2 Withdrawn
NCT02095119 2015-04-14
A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer
National Institute of Cancerología
Phase 1/2 Completed
NCT00551122 2013-01-23
GemTIP
University of Southampton
Phase 1/2 Unknown
NCT00429559 2011-07-22
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 1/2 Completed